Cargando…

Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015–2021

INTRODUCTION: We examined overall survival (OS) benefits for targeted cancer drugs recommended for List of Essential Medicines (EMLs) since 2015. We assessed consistency of decisions in 2019 and 2021 with more specific criteria: OS benefit >4 months and high scores on European Society for Medical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Yue, Naci, Huseyin, Chen, Dingyi, Bai, Lin, Shi, Luwen, Guan, Xiaodong, Wagner, Anita Katharina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546158/ https://www.ncbi.nlm.nih.gov/pubmed/37775106 http://dx.doi.org/10.1136/bmjgh-2023-012899

Ejemplares similares

Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020
por: Zhang, Yichen, et al.
Publicado: (2022)

Evidence of clinical benefit of WHO essential anticancer medicines for children, 2011–2021
por: Bai, Lin, et al.
Publicado: (2023)

Differences in reimbursement listing of anticancer therapies in China: an observational study
por: Guan, Xiaodong, et al.
Publicado: (2020)

Back to the ‘essence’ of medical treatment in oncology: the 2015 WHO Model List of Essential Medicines
por: Eniu, Alexandru, et al.
Publicado: (2016)

Comparative Analysis of ADR on China's National Essential Medicines List (2015 Edition) and WHO Model List of Essential Medicines (19th Edition)
por: Zheng, Fangfang, et al.
Publicado: (2018)

National List of Essential Medicines, 2015: Endocrinology perspective
por: Kalra, Sanjay
Publicado: (2016)

Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
por: Davis, Courtney, et al.
Publicado: (2017)

Anticancer medicines in China: Trends in daily therapy cost and relative procurement volume and spending
por: Huang, Tao, et al.
Publicado: (2021)

A comparative analysis of the Libyan national essential medicines list and the WHO model list of essential medicines
por: Mustafa, Asma Abubakr, et al.
Publicado: (2010)

Monographs for medicines on WHO’s Model List of Essential Medicines
por: Roth, Lukas, et al.
Publicado: (2018)

Revising the WHO Essential Medicines List for paediatric rheumatology
por: Scott, Christiaan, et al.
Publicado: (2021)

The WHO list of essential in vitro diagnostics: Development and next steps
por: Moussy, Francis Gabriel, et al.
Publicado: (2018)

Revising the WHO Essential Medicines List for paediatric rheumatology update
por: Slamang, Waheba, et al.
Publicado: (2022)

List of benefits
por: CERN, Health Insurance Scheme
Publicado: (2015)

List of Reviewers 2021
Publicado: (2022)

List of reviewers 2021
Publicado: (2022)

2021 List of Reviewers
Publicado: (2022)

2021 List of Reviewers
Publicado: (2022)

Reviewer List 2021
Publicado: (2022)

List of Reviewers 2021
Publicado: (2022)

List of reviewers 2021
Publicado: (2022)

2015 Reviewer List
Publicado: (2015)

STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies
por: Bossuyt, Patrick M, et al.
Publicado: (2015)

Health Care Utilization and Costs of Patients With Prostate Cancer in China Based on National Health Insurance Database From 2015 to 2017
por: Bai, Lin, et al.
Publicado: (2020)

Medication Use During Pregnancy in Mainland China: A Cross-Sectional Analysis of a National Health Insurance Database
por: Zhang, Jingyuan, et al.
Publicado: (2019)

The impacts of implementation of National Essential Medicines Policies on primary healthcare institutions: a cross-sectional study in China
por: Guo, Zhigang, et al.
Publicado: (2017)

Estimated costs of production and potential prices for the WHO Essential Medicines List
por: Hill, Andrew M, et al.
Publicado: (2018)

Effective coding is key to the development and use of the WHO Essential Diagnostics List
por: McKnight, Jacob, et al.
Publicado: (2019)

Selection of WHO-recommended essential medicines for non-communicable diseases on National Essential Medicines Lists
por: Jarvis, Jordan D., et al.
Publicado: (2019)

JBO 2021 List of Reviewers
Publicado: (2022)

List of the International Reviewers in 2015
Publicado: (2015)

Safety of medication use during pregnancy in mainland China: based on a national health insurance database in 2015
por: Zhang, Jingyuan, et al.
Publicado: (2019)

NOACs Added to WHO’s Essential Medicines List: Recommendations for Future Policy Actions
por: Di Cesare, Mariachiara, et al.
Publicado: (2020)

Estimation of cost-based prices for injectable medicines in the WHO Essential Medicines List
por: Gotham, Dzintars, et al.
Publicado: (2019)

Essential medicines for mental disorders: comparison of 121 national lists with WHO recommendations
por: Todesco, Beatrice, et al.
Publicado: (2023)

A survey of availability, price and affordability of essential medicines from 2011 to 2016 in Chinese secondary and tertiary hospitals
por: Guan, Xiaodong, et al.
Publicado: (2018)

Effects of the Full Coverage Policy of Essential Medicines on Inequality in Medication Adherence: A Longitudinal Study in Taizhou, China
por: Guo, Zhigang, et al.
Publicado: (2022)

Endocrinology and the essential list
por: Kalra, Sanjay, et al.
Publicado: (2012)

Influence of government price regulation and deregulation on the price of antineoplastic medications in China: a controlled interrupted time series study
por: Guan, Xiaodong, et al.
Publicado: (2019)

List of projects for the VI programme 2021.
por: Delieutraz, Celine
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ontqsck4648bub5ulddfvq60da